

ISIN Code: TW0001795003

Biotechnology and Medical Care

301.0 ▲ 14.0 High 305.5 | Low 287.0 【+/-/X represent Up/Down/Not compared】

Company Information

Company Name	LOTUS PHARMACEUTICAL CO. LTD.
Spokesman	Bjartur Shen
Website	http://www.lotuspharm.com.tw
Capital	NT 2,649,583,120
Main Business	Founded in 1966, Lotus is a leading generic company headquartered in Taiwan with comprehensive product portfolio covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsules. Lotus is actively expanding its businesses in export markets such as US, Japan & China, focusing on high value, difficult-to-make generics. Lotus runs the only plant in Taiwan approved by US FDA, EU EMA, & JP PMDA. In 2014, the fast growing international pharmaceutical Alvogen invested in Lotus via private placement and has thus become its majority shareholder. With Alvogen's global RD, sales & marketing resources, Lotus is now well positioned to become top 5 in APAC region.
Listing Date	2019/12/16
Industry	Biotechnology and Medical Care

Price and Trade Information



Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume
5/17	301.0	12,260,095	5/3	307.5	5,267,458	4/18	321.0	9,060,753
5/16	287.0	5,099,517	5/2	317.0	3,453,314	4/17	333.5	8,033,552
5/15	281.0	3,756,523	4/30	323.0	3,478,631	4/16	334.0	13,975,149
5/14	283.0	3,945,739	4/29	329.0	5,467,526	4/15	332.5	8,662,135
5/13	279.0	10,824,286	4/26	314.5	3,089,031	4/12	342.0	15,599,640
5/10	287.5	4,004,901	4/25	312.0	4,600,753	4/11	325.0	7,588,636
5/9	282.0	4,530,174	4/24	320.5	6,155,348	4/10	326.5	11,054,623
5/8	290.0	4,027,227	4/23	320.5	5,703,729	4/9	323.0	4,925,263
5/7	285.5	10,082,569	4/22	313.0	4,675,028	4/8	325.0	14,081,723
5/6	300.0	4,912,211	4/19	311.5	8,618,851	4/3	317.5	11,647,020

Historical Trading Information

Securities Investment Trust Companies



Foreign Investors




Dealers



Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)	Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)
5/17	+160,500	+748,307	-894,130	4/25	-213,984	-16,622	-381,898
5/16	-960,000	+499,964	+161,000	4/24	+438,000	+48,141	-778,846
5/15	-50,000	-442,457	-536,000	4/23	+389,000	+197,269	-324,860
5/14	-828,000	+94,248	+389,000	4/22	+289,000	+162,848	-676,600
5/13	-1,388,000	+70,284	-93,876	4/19	+55,000	-408,047	+1,322,200
5/10	-122,000	+234,526	-544,000	4/18	-29,000	-149,163	+641,710
5/9	-421,000	-102,430	-617,990	4/17	+38,015	-472,087	-484,800
5/8	-13,000	+105,282	-1,265,000	4/16	+1,515,015	+243,796	+7,330
5/7	-724,000	-398,722	-736,316	4/15	+299,000	-129,781	-1,847,902
5/6	-987,000	-79,764	-22,889	4/12	+1,038,015	+50,571	+4,281,962
5/3	-866,000	-246,208	-451,968	4/11	+661,000	-86,249	-1,303,850
5/2	-167,000	-37,146	-564,200	4/10	+277,016	+166,519	+1,376,053
4/30	+123,016	-31,840	-618,800	4/9	+308,160	-127,994	-824,900
4/29	+3,000	+508,593	+1,281,650	4/8	+515,000	+28,619	+959,172
4/26	+78,000	-117,727	-30,130	4/3	+105,032	+206,457	+26,960

Purchase on Margin




Short Sale




Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale
5/17	-210	+56	5/3	+39	+9	4/18	+182	-17
5/16	+163	-11	5/2	-10	-11	4/17	+110	-42
5/15	+132	+4	4/30	+220	-39	4/16	-415	+28
5/14	-17	+2	4/29	-348	+40	4/15	+792	-129
5/13	-690	-10	4/26	+24	-9	4/12	-1,034	+172
5/10	-63	-4	4/25	+148	-18	4/11	+587	+53
5/9	-314	+9	4/24	+286	-59	4/10	+128	0
5/8	+108	+5	4/23	-12	-9	4/9	+203	0
5/7	+7	-5	4/22	-18	+26	4/8	-396	-5
5/6	+11	-32	4/19	-269	+90	4/3	-454	-241

Company Financials

EPS




Income from continuing operations before tax



Quarter	Jan-Mar		Jan-Jun		Jan-Sep		Jan-Dec	
	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)
2024	3.96	1,306,349	-	-	-	-	-	-
2023	4.58	1,504,572	9.43	3,028,441	14.19	4,594,736	15.72	5,102,925
2022	1.72	588,588	2.97	1,015,379	10.96	3,645,418	11.59	3,940,212
2021	1.85	593,361	3.21	1,077,132	4.54	1,549,780	5.50	1,870,019
2020	0.54	158,681	1.77	536,405	2.92	899,398	4.22	1,304,235
2019	-	-	-	-	-	-	2.74	876,420

Monthly Revenue



Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue
2024/04	2,076,328,000	2023/04	2,017,216,000	2022/04	999,151,000	2021/04	1,157,472,000	2020/04	790,366,000
2024/03	1,150,529,000	2023/03	1,430,185,000	2022/03	1,186,652,000	2021/03	1,100,414,000	2020/03	698,813,000
2024/02	1,051,899,000	2023/02	1,085,919,000	2022/02	1,028,926,000	2021/02	1,015,941,000	2020/02	519,923,000
2024/01	1,995,716,000	2023/01	2,007,756,000	2022/01	945,800,000	2021/01	1,208,009,000	2020/01	745,428,000
2023/12	1,372,425,000	2022/12	1,270,976,000	2021/12	914,162,000	2020/12	1,011,132,000	2019/12	1,734,290,000
2023/11	1,135,020,000	2022/11	1,071,324,000	2021/11	986,367,000	2020/11	957,236,000	2019/11	728,066,000
2023/10	911,653,000	2022/10	829,290,000	2021/10	868,252,000	2020/10	1,023,290,000	2019/10	739,594,000
2023/09	1,100,388,000	2022/09	3,348,921,000	2021/09	1,012,862,000	2020/09	1,020,621,000	2019/09	607,743,000
2023/08	1,184,833,000	2022/08	996,806,000	2021/08	936,958,000	2020/08	747,953,000	2019/08	627,033,000
2023/07	2,287,950,000	2022/07	1,043,645,000	2021/07	1,107,853,000	2020/07	1,116,873,000	2019/07	745,674,000
2023/06	1,103,110,000	2022/06	1,040,734,000	2021/06	1,150,118,000	2020/06	1,052,244,000	2019/06	709,789,000
2023/05	1,321,517,000	2022/05	870,540,000	2021/05	1,156,527,000	2020/05	860,254,000		

PE ratio



Date	PE ratio	Date	PE ratio	Date	PE ratio
5/17	20.16	5/3	19.81	4/18	20.68
5/16	19.22	5/2	20.43	4/17	21.49
5/15	18.82	4/30	20.81	4/16	21.52
5/14	18.96	4/29	21.20	4/15	21.42
5/13	18.69	4/26	20.26	4/12	22.04
5/10	19.26	4/25	20.10	4/11	20.94
5/9	18.17	4/24	20.65	4/10	21.04
5/8	18.69	4/23	20.65	4/9	20.81
5/7	18.40	4/22	20.17	4/8	20.94
5/6	19.33	4/19	20.07	4/3	20.46

Announcements

(Please refer to [mops](#) for the most updated information)

Subject	Date
▶ Lotus Pharmaceutical will convene the online investor conference.	2024/05/06 18:22:19
▶ Lotus Pharmaceutical will attend the investor conference invited by Cathay Securities.	2024/05/06 18:23:05
▶ Announcement of Q1'24 consolidated financial reports approved by Board of Directors	2024/05/09 20:10:48
▶ Announcement of the company's board meeting date of the 2024Q1 consolidated financial report	2024/04/30 19:15:43
▶ Convention of the 2024 Annual General Shareholders' Meeting (Additional discussion item)	2024/04/30 19:17:50

Corporate Action

Year	Shareholders' meeting date	Period	Cash dividends	Stock dividends
2023	-	2023	4.66000	0.00000
2022	-	2022	0.00000	0.00000
2021	-	2021	0.00000	0.00000
2020	-	2020	0.35000	0.00000
2019	2020/06/30	2019	0.00000	0.00000